Clinical trials: Liver Tumor
Hepatocellular Carcinoma
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
A two part study to determine the maximum tolerated dose and/or recommended phase 2 dose of PDR001 in combination with sorafenib in patients with advanced hepatocellular carcinoma in first line.
- Trial name
- NCT02988440
- Testing
- PDR001, Sorafenib
- Where
- 9 sites in United States, Canada and 6 more
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Non-hematologic Malignancies, Metastatic Melanoma
A Phase I Study of ABT-888 in Combination With Temozolomide in Cancer Patients
This Phase I clinical trial is studying the side effects and best dose of ABT-888 when given together with Temozolomide (chemotherapy) in treating patients with solid tumors, including metastatic melanoma (MM), BRCA deficient…
- Conditions
- Non-hematologic Malignancies, Metastatic Melanoma, Breast Cancer, Ovarian Cancer
- Trial name
- NCT00526617
- Testing
- ABT-888, Temozolomide
- Volunteers
- 41 people
- Sponsor
- AbbVie
Metastatic Colorectal Cancer
Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects
To determine if sorafenib when added to chemotherapy will slow disease progression more than chemotherapy alone in patients previously untreated for metastatic colorectal cancer.
- Trial name
- NCT00865709
- Testing
- Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
- Where
- 116 sites in United States, Belgium and 8 more
- Volunteers
- 198 people
- Sponsor
- Bayer
Colon Cancer Liver Metastasis
Hepatic Transarterial Administrations of NKR-2 in Patients With Unresectable Liver Metastases From Colorectal Cancer
The purpose of this study is to test an experimental anti-cancer immunotherapy called NKR-2 (modified T cells), to treat colorectal cancer with unresectable liver metastases.
- Trial name
- LINK (NCT03370198)
- Testing
- NKR-2 cells
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Celyad Oncology SA
Neoplasms, Liver Injury
Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury
This purpose of this study is to evaluate the evaluate the efficacy of Magnesium Isoglycyrrhizinate Injection in the prevention of antineoplastic chemotherapy related acute liver injury.
- Trial name
- MAGIC (NCT01802996)
- Testing
- Magnesium Isoglycyrrhizinate Injection
- Where
- 27 sites in China
- Volunteers
- 2,040 people
- Sponsor
- Cttq
Liver Neoplasms, Hepatocellular Carcinoma
The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER EU/UK)
This trial is a single arm, non-randomized prospective trial. The objective of this trial is to evaluate the efficacy and safety of the HistoSonics System for the treatment of primary or metastatic tumors located in the liver.
- Conditions
- Liver Neoplasms, Hepatocellular Carcinoma, Liver Metastases
- Trial name
- #HOPE4LIVER (NCT04573881)
- Testing
- HistoSonics System
- Where
- 6 sites in Germany, Italy and 2 more
- Volunteers
- 24 people
- Sponsor
- HistoSonics, Inc.
Hepatocellular Carcinoma
Imjudo & Imfinzi PMS
Based on the re-review of new drugs article, Korean pharmaceutical act, the objectives of this study are to assess safety and effectiveness of the study drugs(Imjudo \& Imfinzi) in a real world setting in patients who treated…
- Trial name
- NCT06544629
- Where
- 6 sites in South Korea
- Volunteers
- 246 people
- Sponsor
- AstraZeneca
Ocular Melanoma, Uveal Melanoma
Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
This study will evaluate patients who have ocular melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatments and will be followed until death.
- Trial name
- FOCUS (NCT02678572)
- Testing
- Melphalan/HDS
- Where
- 22 sites in United States, Austria and 7 more
- Volunteers
- 102 people
- Sponsor
- Delcath Systems Inc.
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Carcinoma, Hepatocellular
A Study of GPC3 Redirected Autologous T Cells for Advanced HCC
Intravenous infusion of CART cells in the treatment of solid tumors may be not a suitable choice. Because by intravenous infusion, T cells first entered into the blood circulation, but the number of T cells accumulated at the…
- Trial name
- GPC3-CART (NCT02715362)
- Testing
- TAI-GPC3-CART cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai GeneChem Co., Ltd.
Carcinoma, Hepatocellular
A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
CC-122-HCC-002 is a Phase 1/2 dose escalation and expansion clinical study of CC-122 in combination with nivolumab in subjects with unresectable hepatocellular carcinoma (HCC) who have progressed after or were intolerant to no…
- Trial name
- NCT02859324
- Testing
- CC-122, Nivolumab
- Where
- 14 sites in United States, France and 2 more
- Volunteers
- 21 people
- Sponsor
- Celgene
Hepatocellular Carcinoma, Biliary Tract Cancer
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
GEMINI-Hepatobiliary study will assess the efficacy, safety and tolerability of novel immunomodulators alone and in combination with other anticancer drugs in participants with specified advanced solid tumors.
- Trial name
- NCT05775159
- Testing
- Volrustomig, Bevacizumab, Lenvatinib
- Where
- 46 sites in United States, China and 7 more
- Volunteers
- 294 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma, Metastatic Cancer
GEN2 Directed Cancer Immunotherapy Trial
Phase 1, non-randomized, open label dose escalation clinical trial evaluating the safety of GEN2 in participants with primary \& metastatic liver tumors.
- Trial name
- GEN2 (NCT04313868)
- Testing
- GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
- Where
- 4 sites in Philippines
- Volunteers
- 61 people
- Sponsor
- GenVivo, Inc.
Cancer, Liver Cancer
A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection
The purpose of this study is to determine if PI-88 is effective and safe in patients who have had surgery to remove primary liver cancer.
- Conditions
- Cancer, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- PATRON (NCT01402908)
- Testing
- PI-88
- Where
- 25 sites in China, Hong Kong and 2 more
- Volunteers
- 520 people
- Sponsor
- Cellxpert Biotechnology Corp.
Colorectal Cancer; Lung Cancer
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
Patients with refractory metastatic colorectal cancer or non-small cell lung cancer with liver metastasis treated with Trans-arterial Tirapazamine Embolization along with Pembrolizumab.
- Trial name
- NCT04701476
- Testing
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Where
- 3 sites in United States, Taiwan
- Volunteers
- 110 people
- Sponsor
- Teclison Ltd.
Hepatocellular Carcinoma
To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
The goal of this clinical trial is to assess the efficacy of FB-1603 on improving liver function impairment in hepatocellular carcinoma patients receiving transarterial chemoembolization.
- Trial name
- NCT06478719
- Testing
- FB-1603
- Where
- 2 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- Febico Biomedical Corp.
Hepatocellular Cancer
HCC Patient Preferences in Japan
This non-interventional cross-sectional online survey will evaluate preferences among patients with self-reported HCC. The survey will ask patients to express their preferences regarding descriptions of HCC treatments, which will…
- Trial name
- NCT02616692
- Testing
- Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]
- Where
- Japan
- Volunteers
- 120 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma (HCC) Who Have Been Treated With One Prior Therapy
The purpose of this study is to determine if tivantinib (ARQ 197) is effective in treating patients with MET diagnostic-high hepatocellular carcinoma (liver cancer) who have already been treated once with another therapy.
- Trial name
- METIV-HCC (NCT01755767)
- Testing
- Tivantinib
- Where
- 112 sites in United States, Argentina and 14 more
- Volunteers
- 383 people
- Sponsor
- Daiichi Sankyo
Head and Neck Cancer, Lung Cancer
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Positron Emission Tomography (PET) with fluorine-18 fluoromisonidazole (FMISO) has been used for several years as a non invasive imaging technique to study tumor hypoxia.
- Conditions
- Head and Neck Cancer, Lung Cancer, Liver Cancer
- Trial name
- NCT01213030
- Testing
- [F-18] FMISO, [F-18] HX4
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Siemens Molecular Imaging
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo